Primary localized malignant biphasic mesothelioma of the liver in a patient with asbestosis.

Department of Human Pathology, Kanazawa University Graduate School of Medicine, Kanazawa 920-8640, Japan.
World Journal of Gastroenterology (Impact Factor: 2.37). 03/2009; 15(5):615-21.
Source: PubMed


We report a case of primary localized malignant biphasic mesothelioma of the liver in a 66-year-old man associated with asbestosis. The tumor was detected as a hepatic nodule, 4 cm in diameter, in the right lobe (S8 segment) on CT scan. Histopathological examination demonstrated an intrahepatic tumor with central necrosis consisting of a papillary epithelioid pattern on the surface of the liver, microcystic (microglandular or adenomatoid) pattern mainly in the subcapsular area and sarcomatoid pattern intermingled with microcystic pattern in the major part of the hepatic nodular tumor. Tumor cells, especially of epithelioid type, showed distinct immunoreactivity for mesothelial markers (WT-1, calretinin, D2-40, CK5/6, mesothelin, thrombomodulin) and no immunoreactivity for epithelial (adenocarcinoma) markers (CEA, CD15, BerEP4, BG8, MOC31). P53 immunoreactivity was detected focally in papillary epithelioid tumor cells and extensively in microcystic and sarcomatoid components, suggesting that the papillary epithelioid mesothelioma arose on the surface of the liver, and tumor cells showing microcystic and sarcomatoid patterns invaded and grew into the liver. To date, this is the first case of primary localized malignant biphasic mesothelioma of the liver, since all three primary hepatic mesotheliomas reported so far were epithelioid type.

16 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malignant mesothelioma usually presents with diffuse involvement of the pleura or peritoneum. Circumscribed or localized malignant mesothelioma has been described in these locations, as well as the viscera, in which case it may cause diagnostic confusion with other, more common entities. Herein, we describe the first well-documented case of primary intrapancreatic malignant mesothelioma in the English literature. The patient was an otherwise healthy 39-year-old woman who presented with a symptomatic mass in the head of the pancreas that was completely resected via pancreaticoduodenectomy. The tumor was composed of cysts, papillae, and tubules lined by cells with abundant eosinophilic cytoplasm and immunohistochemically expressed CA-125, calretinin, and D2-40. Follow-up revealed no evidence of residual or recurrent disease 32 months after surgery. This report also describes the clinical and pathologic characteristics of an intrapancreatic mesothelioma and provides a review of the literature regarding entities that may be considered in the differential diagnosis of this tumor.
    Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 02/2010; 456(4):455-61. DOI:10.1007/s00428-010-0885-9 · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A 50-year-old woman presented with upper abdominal pain for 2 months. Abdominal enhanced CT showed multiple hypodense cystic tumors in the liver with heterogeneous enhanced septations. FDG PET/CT showed hypermetabolic peripheral regions and internal septations of the tumors with SUVmax of 6.3. Multiple hepatic cystadenocarcinomas were suspected. The patient underwent resection of the tumors. Epithelial mesothelioma was confirmed by pathology. This case indicates primary hepatic mesothelioma should be added to the differential diagnosis of FDG-avid malignant hepatic tumors.
    Clinical nuclear medicine 03/2013; 39(7). DOI:10.1097/RLU.0b013e31828da61d · 3.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary peritoneal mesothelioma is a rare neoplasm which carries a dismal prognosis. These highly aggressive tumors arise from mesothelial cells lining the peritoneum and are rapidly fatal. The neoplasm is typically associated with crocidolite asbestos exposure. We present the case of a 75-year-old man with primary peritoneal mesothelioma, with invasion into the right hepatic lobe.
    Clinical imaging 08/2013; 37(6). DOI:10.1016/j.clinimag.2013.07.009 · 0.81 Impact Factor
Show more